DDMS is a mechanism-based, irreversible inhibitor that has about 10-fold selectivity for the CYP4A11 (CYP450 4A2) enzyme which predominantly synthesizes 20-HETE in the mammalian kidney. DDMS administration in whole anesthetized rats (10 mg/kg) largely ablates the hypotension and vasodilation induced by nitric oxide donors such as NONOates. Biosynthesis of 20-HETE from arachidonic acid by the CYP4A11 (cytochrome P450 4A) isoforms is an important component of vascular homeostasis, especially in renal circulation. Specification: 0.98 Molecular Formula: C13H23Br2NO3S Molecular Weight: 433.2 PubChem CID: 11212661 Isomeric SMILES: CS(=O)(=O)NC(=O)CCCCCCCCCC=C(Br)Br Related Documents: https://ald-pub-files.oss-cn-shanghai.aliyuncs.com/aladdinsci/pdp/sds/1/D344397-SCI_5e40523e424ebcb28a105360d7446631.pdf
- UPC:
- 12352005
- Condition:
- New
- Availability:
- 8-12 weeks
- Weight:
- 0.96 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- D344397-5mg
- CAS:
- 206052-03-1
- Product Size:
- 5mg
- Precautionary Statement Codes:
- P264
